First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Subscribe To Our Newsletter & Stay Updated
